Shilanski & Associates, Inc. Galapagos Nv Transaction History

Shilanski & Associates, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$122.47 - $213.56 $202,565 - $353,228	-1,654 Closed	0 $0
Q2 2020 Jul 31, 2020	BUY	$185.52 - $231.25 $13,728 - $17,112	74 Added 4.68%	1,654 $326,000
Q1 2020 Apr 14, 2020	BUY	$143.0 - $274.03 $7,722 - $14,797	54 Added 3.54%	1,580 $310,000
Q4 2019 Jan 30, 2020	SELL	$146.12 - $215.82 $3,068 - $4,532	-21 Reduced 1.36%	1,526 $316,000
Q3 2019 Oct 25, 2019	SELL	$130.44 - $187.64 $9,130 - $13,134	-70 Reduced 4.33%	1,547 $236,000
Q2 2019 Aug 05, 2019	BUY	$111.45 - $128.93 $180,214 - $208,479	1,617 New	1,617 $208,000

12.3M

69.1K

42.7K

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $1.58B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

Get notified when there are updates to the investment portfolio of Shilanski & Associates, Inc., based on Form 13F filings with the SEC.

Stay updated on Shilanski & Associates, Inc. with notifications on news.